Notice Number: NOT-CA-19-037

Key Dates
Release Date: March 27, 2019

Issued by
National Cancer Institute (NCI)

Purpose

The purpose of this Notice is to inform potential applicants about a correction in RFA-CA-19-007 "The Experimental Therapeutics Clinical Trials Network (UM1 Clinical Trial Not Allowed)" to clarify that foreign (Canadian) institutions are allowed as "foreign components".

The corrections apply to Section III.1. Eligible Applicants:

1) The sentence (above the heading "Foreign Institutions") to be corrected currently reads:

"The only foreign institutions eligible to apply in response to this FOA are Canadian institutions."

This sentence is corrected to read:

"The only foreign institutions eligible to apply in response to this FOA or serve as foreign components are Canadian institutions."

2) The third clause under the heading "Foreign Institutions" to be corrected currently reads:

"Foreign components, as defined in the NIH Grants Policy Statement, are not allowed."

This sentence is corrected to read:

"Foreign components, as defined in the NIH Grants Policy Statement, are allowed."

All other aspects of RFA-CA-19-007 remain unchanged.

Inquiries

Please direct all inquiries to:

S. Percy Ivy, MD
National Cancer Institute (NCI)
Telephone: 240-276-6565
Email: to ivyp@ctep.nci.nih.gov